Phase I/II study of R340 (Capecitabine), L-OHP (Oxaliplatin) and R435 (Bevacizumab) in advanced and/or metastatic colorectal cancer
Phase 1
- Conditions
- Advanced and/or metastatic colorectal cancer
- Registration Number
- JPRN-jRCT2080220262
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
No previously treated for advanced or metastatic disease, PS 0-1
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method